One in six men will develop prostate cancer. It is the second leading cause of cancer death amongst men in both the US and the EU. Definite diagnosis at an early stage is vital for survival and early treatment minimizes the risk of adverse effects, such as incontinence, erectile dysfunction, or impotence. While there is no preventive screening there is a ray of hope. Prof. Jelle Barentsz,…
Pathology is the gold standard of prostate diagnostics. Whilst the radiologist makes interpretations based on shadows and grey scale values visible on an image, the pathologist has the ‘fait accompli’ under the microscope. Professor Glen Kristiansen, Director at the Institute for Pathology at the University Hospital Bonn, explains why image-guided biopsies also make sense from the…
What you see is what you get - unfortunately, this doesn’t always apply in cancer imaging. Why is it that something which looks conspicuous on an image later turns out not to be a tumour? Why, on the other hand, are things overlooked that later turn out to be cancer? Pathological findings are extremely important to help improve diagnostic precision in radiology. Both disciplines therefore…
A screening method that combines a traditional PSA test with an MRI detects a significantly greater number of prostate cancer cases and improves diagnostic accuracy. The study was conducted as part of the largest international research project on prostate cancer. The method will now be tried with 40,000 subjects in Gothenburg.
Results from a randomised controlled trial to compare the use of permanent radioactive implants (brachytherapy) with dose-escalated external beam radiotherapy in patients with prostate cancer show that the men who received brachytherapy were twice as likely to be cancer-free five years later. These results presented Professor James Morris, from the Department of Radiation Oncology, Vancouver…
Spring can be felt, though many visitors of ECR 2015 probably only have time to enjoy the floral decorations in the conference center. The program of the conference is packed full of topics that promise exciting days and many discussions.
'We desperately need a ‘no treatment’ trial for DCIS', says Clive Wells, Chairman of the European Working Group on Breast Cancer Pathology, and London Regional Co-ordinator for the United Kingdom’s National Health Service (NHS) National Breast Cancer Screening Programme. Interview: Frank Swain
Finnish pharma company Orion and German healthcare giant Bayer have entered into an agreement for the development and commercialisation of a novel drug targeting prostate cancer.
The multiple benefits of PET/CT are undisputed – one being the fact that radiopharmaceuticals, which are used at pico and nano levels – are not toxic.
The “State of Oncology 2013” report by the International Prevention Research Institute [IPRI] warns that the global number of new cancer cases will have doubled between 2008 and 2030.
Prostate cancer is the most common cancerous disease in men. Since magnetic resonance imaging (MRI) arrived the diagnostic capabilities for early detection have improved considerably, along with more selective prostate cancer treatment.
Widely considered a safe procedure for targeted tissue sampling, the fusion of MR and ultrasound images for prostate biopsy purposes is quickly gaining ground among radiologists.
Statistically speaking every fourth older German man suffers from prostate cancer with the mortality rate being 60,000 patients annually
Israel - Researchers are using breath-test technology to detect volatile organic compounds to tell whether a patient has stomach cancer.
UK researchers are working on a new MRI technique called hyperpolarised MRI – or Dynamic Nuclear Polarisation (DNP) – that can utilise more of the available nuclei than traditional MRI, helping to overcome some of its limitations by increasing sensitivity 10,000-fold or more. DNP is part of a longer-term aim to improve cancer mortality with the help of novel cancer imaging tools.
Cancer specialists everywhere increasingly face new findings from molecular biology. Genetic profiling of tumours opens up entirely new perspectives on the disease. How to cope with and integrate new insights into cancer diagnosis and treatment was among key issues discussed at the 2nd European Forum on Oncology, held in Berlin this May
Making prostate cancer therapy more effective, more comfortable for patients and less expensive for society? Dose escalation, up to 80 Gy and above, may be necessary to successfully treat localised prostate cancer with radiotherapy (RT).
A team of researchers at Rigshospitalet has found a new and simple way of detecting testicular cancer before it starts. This discovery will benefit patients in both Denmark and abroad.
Around for almost 20 years, minimally invasive technologies such as laparoscopy and robot-assisted surgery are popular subjects – and aired again during the 27th EAU Congress held in February at the Palais des Congrès, Paris.
Detecting prostate cancer with transrectal ultrasound using strain elastography is quite tricky: it works by applying pressure to the transducer to measure relative stiffness of tissue, Professor Correas points out and states that ‘more than 80 percent of prostate cancer develops in the peripheral zone which is against the rectal wall. If we apply pressure to this zone the deformation of the…
A new urine test can help aid early detection of and treatment decisions about prostate cancer, a study from the University of Michigan Comprehensive Cancer Center and the Michigan Center for Translational Pathology finds.
During the IFCC and EuroMedLab congress in Berlin, Beckmann Coulter launched into Europe its AU 5800, which, the firm reports, improves processing time compared to current systems and therefore meets the demands of ever faster workflow in clinical laboratories.
HI-RTE allows the assessment and real-time colour display of tissue elasticity. The current generation ultrasound modality has proven applications in breast, prostate, thyroid and pancreatic disease and where diagnostic biopsy is indicated, HI-RTE allows more accurate localization and targeting of lesions.
Prostate cancer is the most frequently diagnosed cancer in males in developed countries and the sixth leading cause of cancer death worldwide. One reason for the increase in diagnosis is the widespread uptake of the prostate-specific antigen (PSA) test, capable of detecting slow growing cancers that might otherwise go undetected.